Form 4: Revance Therapeutics President & CEO Foley Disposes of Shares in Merger with Crown Laboratories
SEC Form 4 Filing
Mark J. Foley, President & CEO of Revance Therapeutics, reports the disposition of shares and restricted stock units following the merger agreement with Crown Laboratories.
Summary
- Mark J. Foley, President & CEO of Revance Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- The filing reflects transactions related to the merger agreement between Revance Therapeutics and Crown Laboratories, Inc.
- Foley disposed of 996,935 shares of common stock at $3.65 per share as part of a cash tender offer.
- Unvested restricted stock units (RSUs) and performance-based restricted stock units (PSUs) were canceled and converted into cash payments based on the merger agreement terms.
- Foley acquired 84,686 shares related to performance-based restricted stock units (PSUs) as part of the merger agreement.
- The reporting person has direct ownership of 27,933 shares of common stock.
- The reporting person has indirect ownership of 110,913 shares of common stock held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.
Sentiment
Score: 6
Explanation: Neutral sentiment as the document primarily reports transactions related to a previously announced merger. The information is factual and does not convey a positive or negative outlook.
Positives
- The merger provides liquidity to shareholders through a cash tender offer.
Future Outlook
The document primarily reports on past transactions related to the merger; no specific future outlook is provided beyond the completion of the merger.
Industry Context
This announcement reflects consolidation activity within the biotechnology or pharmaceutical industry, where mergers and acquisitions are common strategies for growth and market expansion.
Comparison to Industry Standards
- Mergers and acquisitions are a common strategy in the pharmaceutical and biotechnology industries.
- Comparable transactions often involve similar cash tender offers and conversion of equity awards into cash payments.
- The $3.65 per share price would need to be compared to other similar acquisitions to assess its relative value.
Stakeholder Impact
- Shareholders received cash for their shares as part of the merger.
- Employees with unvested equity awards received cash payments.
Key Dates
| Date | Description |
|---|---|
| 2002/04/10 | Date of Foley Family Trust U/A DTD |
| 2023/01/31 | Date of PSU grant |
| 2024/12/07 | Date of Amended and Restated Agreement and Plan of Merger |
| 2025/02/04 | Date of transaction involving disposal of common stock |
| 2025/02/06 | Date of transaction involving acquisition and disposal of common stock |
Keywords
Revance Therapeutics, Crown Laboratories, Merger, Form 4, Beneficial Ownership, Shares, RSU, PSU, Foley, Tender Offer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.